Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

STRING v10: protein–protein interaction networks, integrated over the tree of life

Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · see citing works

The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible

Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980 · see citing works

Death Receptors: Signaling and Modulation

Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · see citing works

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer

Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · see citing works

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482 · see citing works

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Boyerinas, B., Jochéms, C., Fantini, M. C., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468 · see citing works

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J. N., Alumkal, J. J., Drake, C. G., THOMAS, G. V., Redmond, W. L., Farhad, M. E., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 360 · see citing works

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 356 · see citing works

The functional characterization of interleukin-10 receptor expression on human natural killer cells

Carson, W. E., Lindemann, M. J., Baiocchi, R. A., Linett, M. L., Tan, J., Chou, C., Narula, S. K., & Caligiuri, M. A. (1995) · Blood · doi:10.1182/blood.v85.12.3577.bloodjournal85123577 · Cited by 187 · see citing works

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

Jochéms, C., Hodge, J. W., Fantini, M. C., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Tsang, K. Y., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182 · see citing works

The DNA Damage Response Arouses the Immune System

Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178 · see citing works

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 128 · see citing works

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Fujii, R., Friedman, E. R., Richards, J., Tsang, K. Y., Heery, C. R., Schlom, J., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9256 · Cited by 110 · see citing works

The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality

Papadimitriou, M., Mountzios, G., & PAPADIMITRIOU, C. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.010 · Cited by 108 · see citing works

Combination Strategies to Enhance Antitumor ADCC

Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 97 · see citing works

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

Dougherty, B. A., Lai, Z., Hodgson, D., Orr, M. C. M., Hawryluk, M. J., Sun, J. X., Yelensky, R., Spencer, S., Robertson, J. D., Ho, T. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17613 · Cited by 97 · see citing works

Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity

Hamilton, G., & Rath, B. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1294156 · Cited by 71 · see citing works

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer

Nowsheen, S., Bonner, J. A., LoBuglio, A. F., Trummell, H. Q., Whitley, A. C., Dobelbower, M. C., & Yang, E. S.-H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024148 · Cited by 70 · see citing works

Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer

Li, J., Wang, R., Kong, Y., Broman, M. M., Carlock, C., Chen, L., Li, Z., Farah, E., Ratliff, T. L., & Liu, X. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0361 · Cited by 60 · see citing works

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

Plummer, R., Swaisland, H., Leunen, K., van Herpen, C. M. L., Jérusalem, G., Grève, J. D., Lolkema, M. P., Soetekouw, P. M. M. B., Mau‐Sørensen, M., Nielsen, D. L., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2836-2 · Cited by 53 · see citing works

Immunotherapy for Prostate Cancer: Where We Are Headed

Schepisi, G., Farolfi, A., Conteduca, V., Martignano, F., Lisi, D. D., Ravaglia, G., Rossi, L., Menna, C., Bellia, S. R., Barone, D., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122627 · Cited by 53 · see citing works

A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Karzai, F., Madan, R. A., Owens, H., Couvillon, A., Hankin, A., Williams, M., Bilusic, M., Cordes, L. M., Trepel, J. B., Killian, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.163 · Cited by 50 · cited 3× · see citing works

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody

Jochéms, C., Hodge, J. W., Fantini, M. C., Tsang, K. Y., Vandeveer, A. J., Gulley, J. L., & Schlom, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30767 · Cited by 50 · see citing works

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer

Hijaz, M., Chhina, J., Mert, İ., Taylor, M., Dar, S. A., Al-Wahab, Z. R., Ali‐Fehmi, R., Buekers, T., Munkarah, A. R., & Rattan, R. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.06.005 · Cited by 31 · see citing works

A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab

Fujii, R., Schlom, J., & Hodge, J. W. (2017) · Journal of neurosurgery · doi:10.3171/2017.1.jns162610 · Cited by 31 · see citing works

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer

García-Parra, J., Dalmases, A., Morancho, B., Arpí, O., Menéndez, S., Sabbaghi, M., Zazo, S., Chamizo, C., Madoz‐Gúrpide, J., Eroles, P., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.004 · Cited by 29 · see citing works

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

Yonemori, K., Tamura, K., Kodaira, M., Fujikawa, K., Sagawa, T., Esaki, T., Shirakawa, T., Hirai, F., Yokoi, Y., Kawata, T., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3106-7 · Cited by 27 · see citing works

Modulation of transcriptional activity of p53 by ultraviolet radiation: Linkage between p53 pathway and DNA repair through damage recognition

Zhu, Q., Wani, M. A., El-Mahdy, M. A., Wani, G., & Wani, A. A. (2000) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200008)28:4 · Cited by 19 · see citing works

Olaparib and somatic BRCA mutations

George, A. J., Banerjee, S. N., & Kaye, S. B. (2017) · Oncotarget · doi:10.18632/oncotarget.18419 · Cited by 16 · see citing works

NK Cell Phenotypic and Functional Heterogeneities and Molecular Mechanisms of Cytotoxicity

Bonavida, B. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014010804 · Cited by 11 · see citing works

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy

Pérez-López, R., Roda, D., Jiménez, B., Brown, J. S., Mateo, J., Carreira, S., Lopez, J. S., Banerji, U., Molife, L. R., Koh, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22303 · Cited by 8 · see citing works

Abiraterone–Olaparib Combo Aids Men with mCRPC

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2018-084 · Cited by 2 · see citing works

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220 · see citing works

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works

Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162 · see citing works

Leveraging NKG2D Ligands in Immuno-Oncology

Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 151 · see citing works

Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors

Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 134 · see citing works

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Fabian, K. P., Wolfson, B., & Hodge, J. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728018 · Cited by 125 · see citing works

The DNA Damage Response and Inflammation in Cancer

Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 110 · see citing works

NK cell-based therapeutics for lung cancer

Pockley, A. G., Vaupel, P. W., & Multhoff, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1688298 · Cited by 86 · see citing works

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future

Lamb, M. G., Rangarajan, H. G., Tullius, B. P., & Lee, D. A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02277-x · Cited by 79 · see citing works

Harnessing natural killer cells for the treatment of ovarian cancer

Evert, J. S. H., Bekkers, R. L. M., Ottevanger, N. P. B., Jansen, J. H., Massuger, L. F. A. G., & Dolstra, H. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.020 · Cited by 78 · see citing works

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 71 · see citing works

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers

Lee, E. K., & Konstantinopoulos, P. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920944116 · Cited by 71 · see citing works

Recent advances and future perspectives in the therapeutics of prostate cancer

Varaprasad, G. L., Gupta, V., Prasad, K., Kim, E., Tej, M. B., Mohanty, P., Verma, H. K., Raju, G. S. R., Bhaskar, L. V., & Huh, Y. S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00444-9 · Cited by 69 · see citing works

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

Yélamos, J., Moreno-Lama, L., Jimeno, J., & Ali, S. O. (2020) · Cancers · doi:10.3390/cancers12020392 · Cited by 69 · see citing works

Overcoming hypoxia-induced functional suppression of NK cells

Solocinski, K., Padget, M. R., Fabian, K. P., Wolfson, B., Cecchi, F., Hembrough, T., Benz, S. C., Rabizadeh, S., Soon‐Shiong, P., Schlom, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000246 · Cited by 69 · see citing works

PARP mediated DNA damage response, genomic stability and immune responses

Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 67 · see citing works

Natural Born Killers: NK Cells in Cancer Therapy

Franks, S. E., Wolfson, B., & Hodge, J. W. (2020) · Cancers · doi:10.3390/cancers12082131 · Cited by 65 · see citing works

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 58 · see citing works

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

Seeber, A., Zimmer, K., Kocher, F., Puccini, A., Xiu, J., Nabhan, C., Elliott, A., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000942 · Cited by 52 · see citing works

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data

Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 44 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Palicelli, A., Bonacini, M., Croci, S., Magi‐Galluzzi, C., Cañete‐Portillo, S., Chaux, A., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., et al. (2021) · Cells · doi:10.3390/cells10113166 · Cited by 41 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212330 · Cited by 40 · see citing works

A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?

Heidegger, I. M., Necchi, A., Pircher, A., Tsaur, I., Marra, G., Kasivisvanathan, V., Kretschmer, A., Mathiéu, R., Ceci, F., van den Bergh, R. C. N., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.10.010 · Cited by 38 · see citing works

Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer

Russell, É., Conroy, M. J., & Barr, M. P. (2022) · Cells · doi:10.3390/cells11040605 · Cited by 37 · see citing works

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation

Fabian, K. P., Kowalczyk, J. T., Reynolds, S. T., & Hodge, J. W. (2022) · Cells · doi:10.3390/cells11233826 · Cited by 36 · see citing works

Ovarian cancer treatment and natural killer cell-based immunotherapy

Fan, Z., Han, D., Fan, X., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308143 · Cited by 34 · see citing works

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Schofield, D. J., Percival‐Alwyn, J., Rytelewski, M., Hood, J., Rothstein, R. P., Wetzel, L. K., McGlinchey, K., Adjei, G., Watkins, A., Machiesky, L., et al. (2021) · mAbs · doi:10.1080/19420862.2020.1857100 · Cited by 29 · see citing works

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing

Wolfson, B., Padget, M. R., Schlom, J., & Hodge, J. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002258 · Cited by 28 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes

Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020236 · Cited by 25 · see citing works

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system

Bound, N. T., Vandenberg, C. J., Kartikasari, A. E. R., Plebanski, M., & Scott, C. L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886170 · Cited by 25 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Palicelli, A., Bonacini, M., Croci, S., Magi‐Galluzzi, C., Cañete‐Portillo, S., Chaux, A., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., et al. (2021) · Cells · doi:10.3390/cells10113165 · Cited by 24 · see citing works

Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions

López‐Campos, F., Gajate, P., Romero-Laorden, N., Zafra, J., Juan, M., Polo, S. H., Conde-Moreno, A. J., & Couñago, F. (2022) · Biomedicines · doi:10.3390/biomedicines10030537 · Cited by 23 · see citing works

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia

Liu, Y., Song, H., Song, H., Feng, X., Zhou, C., & Huo, Z. (2019) · AMB Express · doi:10.1186/s13568-019-0836-z · Cited by 22 · see citing works

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma

Ferretti, L. P., Böhi, F., Pedrioli, D. M. L., Cheng, P. F., Ferrari, E., Baumgaertner, P., Alvarado-Diaz, A., Sella, F., Cereghetti, A., Turko, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0485 · Cited by 20 · see citing works

Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies

Ajina, R., Zahavi, D. J., Zhang, Y., & Weiner, L. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.005 · Cited by 18 · see citing works

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting

Wu, Z., Tao, H., Zhang, S., Wang, X., Ma, J., Li, R., Liu, Z., Wang, J., Cui, P., Chen, S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02852-4 · Cited by 16 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1

Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212314 · Cited by 16 · see citing works

The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors

Piccinelli, S., Romee, R., & Shapiro, R. M. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.02.002 · Cited by 15 · see citing works

New Prospects for Molecular Targets for Chordomas

Ozair, M. Z., Shah, P. P., Mathios, D., Lim, M. K., & Moss, N. S. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.11.004 · Cited by 15 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)

Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212297 · Cited by 14 · see citing works

PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-<?A3B2 tf="TT2cba4af3_B"?>кB pathway activity and DNA damage response induced by Idarubicin

Ke, B., Li, A., Fu, H., Kong, C., Liu, T., Zhu, Q., Zhang, Y., Zhang, Z., Chen, C., & Jin, C. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2021011 · Cited by 12 · see citing works

Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment

Catalano, M., Iannone, L. F., Cosso, F., Generali, D., Mini, E., & Roviello, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2158813 · Cited by 12 · see citing works

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy

Palicelli, A., Bonacini, M., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121312 · Cited by 11 · see citing works

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers

Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 10 · see citing works

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies

Kowalczyk, J. T., Fabian, K. P., Padget, M. R., Lopez, D. C., Hoke, A. T. K., Allen, C. T., Hermsen, M. A. J. A., London, N. R., & Hodge, J. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005752 · Cited by 9 · see citing works

TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment

Pruitt, M. R., Fabian, K. P., Lee, J., & Hodge, J. W. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0438 · Cited by 8 · see citing works

Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy

Liu, Q., Zhang, C., Gao, Y., Feng, D., Deng, D., & Pan, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04101-9 · Cited by 6 · see citing works

Next Generation Therapeutic Strateg‐Es: Evolving cancer immunotherapy through agents that Engage, Expand and Enable the anti‐tumor immune response

Wolfson, B., & Hodge, J. W. (2021) · ImmunoMedicine · doi:10.1002/imed.1020 · Cited by 6 · see citing works

Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours

Lutfi, N., Galindo-Campos, M. A., & Yélamos, J. (2021) · Cancers · doi:10.3390/cancers13236008 · Cited by 6 · see citing works

Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions

Zhou, Z., Zhao, K., Xiao, X., Yang, W., Miao, Y., Wu, T., Kong, X., Tao, Y., Wang, W., & Dong, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105208 · Cited by 5 · see citing works

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses

Moran, J., Mylod, E., Kane, L. E., Marion, C., Keenan, E., Mekhaeil, M., Lysaght, J., Dev, K. K., O'Sullivan, J. N., & Conroy, M. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020360 · Cited by 4 · see citing works

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Zhang, Y., Liang, L., Li, Z., Huang, Y., Jiang, M., Zou, B., & Xu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1295579 · Cited by 3 · see citing works

Oxidative Stress in the Tumor Immune Microenvironment

Wang, Y., Hu, Y., Jiang, Y., & Zhou, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_2 · Cited by 3 · see citing works

Removal of evolutionarily conserved functional MYC domains in a tilapia cell line using a vector-based CRISPR/Cas9 system

Kim, C., Cnaani, A., & Kültz, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-37928-x · Cited by 3 · see citing works

Immunotherapeutic strategies and immunotherapy resistance in prostate cancer

Deb, A., Patel, N., Patel, P. A., Kilinc, E., Hachem, S., Elajami, M. K., & Mansour, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00010-5 · Cited by 3 · see citing works

Olaparib for the Treatment of Metastatic Prostate Cancer

Maurice‐Dror, C., Wyatt, A. W., & Chi, K. N. (2021) · Future Oncology · doi:10.2217/fon-2020-1245 · Cited by 3 · see citing works

Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

Liu, Q., Zhang, C., Gao, Y., Feng, D., Deng, D., & Pan, Y. (2025) · Advanced Biology · doi:10.1002/adbi.202400720 · Cited by 1 · see citing works

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Dirk, B. S., Weir, G. M., Quinton, T., Hrytsenko, О., & Stanford, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-82108-4 · Cited by 1 · see citing works

Current approaches to assessing the biological activity of immunocytokines in vitro

Konoplina, K. M., Kosobokova, E. N., & Kosorukov, V. S. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-3-10-22 · Cited by 1 · see citing works

Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145

Schneider, R., Gademann, G., Ochel, H.-J., Neumann, K., Jandrig, B., Hass, P., Walke, M., Schostak, M., Brunner, T. B., & Christoph, F. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01859-6 · Cited by 1 · see citing works

Carving a niche for immunotherapy in ovarian cancer

Gupta, N., Lampert, E. J., & Lee, J. (2021) · Oncotarget · doi:10.18632/oncotarget.27864 · Cited by 1 · see citing works

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition

Fenerty, K. E., Padget, M. R., Wolfson, B., Gameiro, S. R., Su, Z., Lee, J. H., Rabizadeh, S., Soon‐Shiong, P., & Hodge, J. W. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0715-9

Natural Killer Cells in Lung Cancer

Ghobadinezhad, F., Izadi, Z., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_283

Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective

Feng, X., Chai, Y.-H., Jiang, K., Jiang, W., Chen, W.-C., & Pan, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i11.4489

Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study

Tao, H., Liu, Y., Wang, L., Wang, J., Ma, J., Zhang, G., Liu, Z., & Hu, Y. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.08.005

The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803

Lee, C.-Y., Schlom, J., Hodge, J. W., & Fabian, K. P. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04260-4

PARP inhibitors restore NK cell function via secretory crosstalk with tumor cells in prostate cancer

Chao, Z., Li, L., Hao, X., Peng, H., Wang, Y., Zhang, C., Guo, X., Liu, P., Ma, S., Zhang, J., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci197157

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

Santiago-Sánchez, G. S., Rosato, F., Fabian, K. P., Padget, M. R., Lee, J.-M., Karzai, F. H., Schlom, J., Gulley, J. L., Hamilton, D. H., Lee, J. K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014518

Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition.

Fenerty, K. E., Padget, M. R., Schlom, J., & Hodge, J. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5021

Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.

Simmons, A. D., Robillard, L., Nguyen, M., Harding, T. C., & Charych, D. H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5582

Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer

Gohari, Z., Stojanovic, L., & Rassool, F. V. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0831 · Cited by 8 · see citing works

PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor

Wang, S., Yu, X., Qian, Y., Pan, W., Huang, P., Jin, N., Li, X., Xu, C., Liu, D., Zhao, G., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101247 · Cited by 6 · see citing works

Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma

Chen, G., Wu, J., Song, W., Li, H., Shi, C., Gao, Y., Shi, Z., Li, Z., & Zhang, M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05359-3 · Cited by 4 · see citing works